Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral nicotinamide plus topical hydroquinone for primary macular amyloidosis
IRCT20251211068289N3Phase 3Not yet recruiting
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in Macular Amyloidosis comparing Topical hydroquinone plus oral nicotinamide with Topical hydroquinone plus oral placebo (2 arms). Primary endpoints: Pruritus severity and Pigmentation severity. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
nicotinamidehydroquinone
03
Conditions
Macular Amyloidosis
Beyond the preview
Go deeper on IRCT20251211068289N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251211068289N3.